Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park CapitalGlobeNewsWire • 03/30/20
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business UpdateGlobeNewsWire • 03/26/20
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New ZealandGlobeNewsWire • 12/12/19
Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus NephritisGlobeNewsWire • 12/09/19
Equillium Featured in Panel Discussion at Capital Markets Day for Kidney HealthGlobeNewsWire • 11/15/19
Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business UpdateGlobeNewsWire • 10/01/19
Equillium to Present at H. C. Wainwright 21st Annual Global Investment ConferenceGlobeNewsWire • 08/27/19